|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||85.74 - 86.54|
|52-week range||76.45 - 106.66|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||16.82|
|Forward dividend & yield||3.33 (3.88%)|
|Ex-dividend date||06 May 2022|
|1y target est||N/A|
Shares of Provention Bio (NASDAQ: PRVB) rose 30.3% in November, according to data from S&P Global Intelligence. The pharmaceutical company closed out October at $6.94 and opened November at $7. The move up can be directly tied to the approval of Provention therapy Tzield (teplizumab-mzwv) by the Food and Drug Administration (FDA) on Nov. 17.
PARIS (Reuters) -French drugmaker Sanofi said on Friday that if it decides to bid for biotech company Horizon Therapeutics Plc, it would do so in cash. Horizon Therapeutics Plc, which has a market capitalization of about $18 billion, is in talks with Amgen Inc, Sanofi and Johnson & Johnson unit Janssen Global Services over potential takeover offers.
(Bloomberg) -- Horizon Therapeutics Plc rose by the most in more than three years after the drug developer disclosed it’s in talks with a trio of potential suitors about a possible sale of the company.Most Read from BloombergScientists Revive 48,500-Year-Old ‘Zombie Virus’ Buried in IceAn Arizona County’s Refusal to Certify Election Results Could Cost GOP a House SeatStock Traders Cheer Powell’s Risk-Friendly Shift: Markets WrapNYC Becomes One Billionaire Family’s Haven From China Property Crash